The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

15 researchers from Lund University Diabetes Centre receive millions in funding

Glass tubes at Clinical Research Centre in Malmö. Photo.
The grants from the Crafoord Foundation will support a wide range of projects in diabetes research. Photo: Kennet Ruona

Researchers from Lund University Diabetes Centre (LUDC) receive 5,3 million SEK in grants from the Crafoord Foundation in southern Sweden.

This year, 15 researchers from LUDC are awarded grants for a wide range of projects in diabetes research. In total, researchers at LUDC receive 5,3 million SEK in grants from the foundation.

– It is great news and an important contribution to support projects spanning several areas of diabetes research, says Line Lundfald, grant manager at LUDC.

Diabetes is a major global health problem, with 1 in 11 adults having diabetes today. The 15 researchers are part of the strategic research area EXODIAB, a research environment that involves diabetes researchers at the LUDC and at Uppsala University. Together, researchers work towards understanding disease mechanisms and developing new therapies to allow better and more personalised prevention and management of diabetes and its complications.

Researchers and projects at LUDC that receive funding from the Crafoord Foundation 2021, SEK:

Emma Ahlqvist, Subclassification of type 2 diabetes – New genes and new mechanisms, 500 000
Sebastian Albinsson, Reprogramming of smooth muscle cells can cause vascular disease – identification of underlying mechanisms and possible treatment methods, 300 000
Klinsmann Carolo Dos Santos, A membrane-centric view on dietary lipids and adipocyte function, 100 000 
Andreas Edsfeldt, Apoptosis and efferocytosis as underlying causes of impaired tissue repair in diabetes-associated cardiovascular complications, 300 000 
Sofia Enhörning, WATer and Environment Related to CArdiovascular, Metabolic and Preeclamptic States (WATERCAMPS), 300 000
Viktor Hamrefors, Cardiovascular autonomic dysfunction – an underestimated and modifiable risk factor for cardiovascular disease and COPD?, 300 000 
Ola Hansson, Development of an exercise mimetic to treat thromboembolism, 200 000 
Sebastian Kalamajski, Investigation of genetic variants in MTIF3, relevant for personalised obesity treatment, 200 000 
Ben King, Roles of C3 in diabetes, 1 200 000 
Marlena Maziarz, National research initiative for a large-scale analysis of symptoms, exposure and risk factors associated with covid-19 infection: COVID Symptom Study in Sweden, 400 000 
Luis Sarmiento-Pérez, Dysregulation of pancreatic beta-cell autophagy – A viral strategy to promote beta-cell dysfunction and type 1 diabetes?, 200 000 
Alexandru Schiopu, Development of a novel immunomodulatory therapy against cardiac inflammation, 300 000 
Emily Sonestedt, Are dietary habits with low climate impact associated with reduced cardiometabolic disease risk?, 300 000 
Karin Stenkula, Mechanosensing and EHD2: key factors regulating adipocyte function, 300 000 
Enming Zhang, Reversal of insufficient insulin secretion in diabetic beta cells by controlling mechanical force stimulated insulin secretion, 400 000